Centre Hospitalier Victor Dupouy
- Address
- lock Available on a paid plan
Centre Hospitalier Victor Dupouy - Advanced Hematology & Oncology Research Center
Centre Hospitalier Victor Dupouy is a leading academic medical center specializing in complex hematologic malignancies and solid tumor research. The institution demonstrates particular expertise in acute leukemias, lymphoproliferative disorders, and innovative immunotherapy trials, with extensive experience in phase 2 and phase 3 clinical investigations across multiple therapeutic areas.
- Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) - novel targeted therapies including FLT3 inhibitors, bispecific antibodies, and allogeneic transplantation strategies
- Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma, and Lymphomas - BTK inhibitors, venetoclax combinations, CAR-T therapies, and maintenance strategies
- Critical Care and Infectious Disease - sepsis management, antimicrobial stewardship, ventilator-associated pneumonia, and immunosuppression in ICU settings
- Solid Tumors - breast cancer (hormonal therapies and CDK4/6 inhibitors), colorectal cancer, head and neck cancer, and anal carcinoma with radiotherapy combinations
The center maintains active research programs in myeloproliferative neoplasms including polycythemia vera and myelodysplastic syndromes, as well as rare hematologic conditions such as blastic plasmacytoid dendritic cell neoplasm and hemophagocytic lymphohistiocytosis. Additional therapeutic focus areas include immune thrombocytopenia, severe asthma and COPD, dermatologic conditions (psoriasis, atopic dermatitis, vitiligo), and invasive fungal infections. The institution's comprehensive portfolio reflects a commitment to advancing precision medicine through biomarker-driven treatment strategies and minimal residual disease monitoring across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 205 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 172 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Victor Dupouy
lock Showing 1 of 78 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Comparative, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Imipenem/Cilastatin-XNW4107 in Comparison with Imipenem/Cilastatin/Relebactam in Adults with Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia | Evopoint Biosciences USA Inc. | Phase III | Not Recruiting | Apr 2024 | Jul 2024 |
IMP list
lock Showing 1 of 205 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 7 | Unknown | 2021-10-08 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.